# A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

> **NCT04122976** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 805 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Darolutamide(Nubeqa, BAY1841788)

## Key facts

- **NCT ID:** NCT04122976
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04122976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04122976, "A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT04122976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*